IAS 2017

Survey: ART, Hormone Tx Interactions Concerning for Transgender Women

By July 28, 2017

The survey included 87 transgender women receiving services at a L.A. community-based AIDS organization.

Clinically Meaningful Reductions in HIV-Related Diarrhea with Long-Term Crofelemer

By July 27, 2017

Data from the analysis showed a 73% mean reduction in diarrhea episodes from baseline after treatment with Mytesi for 24 weeks.

Teens Find Vaginal Ring for HIV Prevention Acceptable

By July 26, 2017

Previous Phase 3 studies enrolling >4,500 women (ASPIRE and The Ring Study) have already demonstrated the vaginal ring to be safe and effective in protecting women aged 18-45 years against HIV.

Doravirine Comparable to Efavirenz in Combination with Other ART for HIV

By July 26, 2017

Doravirine is being investigated in other Phase 3 trials including DRIVE-AHEAD, DRIVE-FORWARD, and DRIVE-SHIFT.

Vaccine Regimens Generate Anti-HIV Immune Responses in Early-Stage Trial

By July 26, 2017

The early-stage clinical trial studied "mosaic" vaccines created to induce immune responses against various HIV subtypes responsible for infections across the world.

Child with HIV Maintains Remission without ART for Over 8 Years

By July 25, 2017

A reservoir of virus incorporated in a small proportion of immune cells was observed but no signs of HIV infection were noted in a 9-year-old child who started anti-HIV therapy at 1 month.

Promising Results for Two-Drug, Long-Acting Injectable HIV Regimen

By July 24, 2017

This Phase 2b trial assessed HIV-1 viral suppression with rilpivirine (Janssen) and cabotegravir (ViiV Healthcare) given together every 4 or 8 weeks.

Fixed-Dose HIV Combo Containing Bictegravir Found to Be Safe, Effective

By July 24, 2017

In addition to these studies, bictegravir in combination with FTC/TAF is also being evaluated in two ongoing studies involving virologically suppressed adult patients.